Novartis' CEO Says Getting Momentum Back in Alcon Unit

The transcript discusses Novartis' strategic review of its Alcon business, highlighting recent growth and potential options like IPOs or spin-offs. It also covers the joint venture with Glaxo, emphasizing the business's growth and future decisions. The impact of US healthcare policies, particularly the repeal of Obamacare and drug pricing, is also discussed, with a focus on ensuring patient access to innovative medicines.

What is the speaker's perspective on the future of healthcare access for patients?

What challenges does the speaker identify regarding drug pricing in the United States?

What approach is the speaker advocating for in terms of healthcare payments?